$Cadrenal Therapeutics (CVKD.US)$ $Abbott Laboratories (ABT.US)$
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial

$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Tuesday, 4th March at 8:00 am
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a late-stage biopharmaceutical company focused on the development of spec...

$Cadrenal Therapeutics (CVKD.US)$ Reuters
4 mins ago
Cadrenal Therapeutics Announces Collaboration Agreement With Abbott in Support of Pivotal Study of Tecarfarin in Patients With Heartmate 3™ Lvad

$Cadrenal Therapeutics (CVKD.US)$
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted a recently published manuscript in the Journal of Cardiac Failure, evaluating the relationship between time in therapeutic range (TTR) management quality and clinical outcomes for left ventricular assist device (LVAD) patients. The findings emphasize the need for improved anticoagulation th...

Needs a clean break of .52 for any move upwards. Here are the levels to watch.
Larger Image: tradingview.com...
$Cadrenal Therapeutics (CVKD.US)$  

$Cadrenal Therapeutics (CVKD.US)$
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
Cadrenal Therapeutics (Nasdaq: CVKD) has presented new data from the ARIES-HM3 trial at the ISHLT conference, showing the significant impact of anticoagulation quality in LVAD patients. The trial highlighted the deficiencies of warfarin and introduced tecarfarin, a novel VKA, as a potential replacement. T...